A venture capital firm with offices in Western Europe current invests from their third fund which focuses on investments in Europe based therapeutics and medical innovation. The firm invests in Europe, and typically allocates €5 to €12 million equity to each portfolio company, generally over several tranches.
The firm invests in therapeutics ventures. The firm is agnostic regarding technologies and indication areas and invests in companies with assets 12 months or less to the clinic, as well as assets in phase 1 or 2. (i.e Series A and Series B)
Moreover, the firm is a company builder, identifying academic projects with potential for company creation. The company has developed a specific model of collaboration between the academic, the firm and an industrial to create companies.
The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
A venture capital firm based in the US invests in companies dedicated to working on the intersection of biology, technology, and data science. The firm is focused on early-stage investments from Seed to Series A and also dedicates funds to follow-on investment. Initial check sizes are usually between $1-2M but can fall outside of this range on a case-by-case basis. The firm will consider global opportunities.
The firm invests in the intersection of biology, technology, and data science and the areas of interest fall beyond traditional sectors. The firm is focused on (1) technology driving biology (miniaturization, automation, data sciences); (2) biology as technology (synthetic biology, genetic engineering, stem cells); (3) biology beyond healthcare (agriculture, chemicals/industrials, consumer). The firm will consider cutting edge therapeutics/drug development and platform technologies and diagnostics, and is not interested in traditional medical devices or digital health.
The firm focuses on privately owned, early stage companies and is open to working with all types of management teams. The firm likes to step in early and prefers to act as the lead investor, but is open to co-investing as well.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
A private investment office is actively involved in the management of a diverse portfolio of investments in private equity and venture capital.
The firm accelerates commercialization of ground-breaking innovation through investments, experienced hands-on management and the intelligent use of partnering. The firm focuses on a number of areas around which it has build teams of senior execs, world leading experts and advisors drawn from industry, finance, academia and regulatory bodies to support and accelerate its ventures.
In Life Sciences, the firm typically invests at seed stage or before a company has been formed and develop these early opportunities through preclinical phase; at late preclinical/early clinical stage the firm gets co-investors involved. The firm prefers areas where there are multiple capital efficient routes to market, with opportunities for early proof of concept or early out-licensing or exits.
Currently, the firm manages a $150M fund and makes investments from $100K to $10M, depending on the opportunity. The firm is seeking a couple of opportunities to add to its portfolio. The firm invests in companies based in the USA and/or Europe.
The firm is sector- and stage- agnostic. In terms of biotech indications, the firm has invested in anti-infectives and particularly antimicrobial resistance, as well as immuno-modulatory anti-inflammatory indications and orphan and rare diseases.
The firm looks for a strong management team with proven track-record and a ground-breaking technology addressing an unmet need. The firm seeks to take significant stakes and board seats. In addition, the firm may provide active support leveraging its network of senior execs, experts and advisors to accelerate the development.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
Life Science Nation’s next conference, Digital RESI March, is coming up in just over a month. We are excited to continue facilitating meaningful connections between early-stage life science companies and investors/strategic partners through this 3-day virtual conference, which will include a robust agenda of investor panels, workshops (including a new educational track), and the Innovator’s Pitch Challenge (IPC), through which we will have life science companies present live pitches in front of a judging panel.
We expect 300+ investors to join the upcoming event. With a 24-hour meeting capacity, attendees will be able to join the conference at the comfort of their home and schedule meetings based on their availability, regardless of what time zone they are in.
Below is a selected list of participating investors that you can expect to meet at Digital RESI March. If you are actively fundraising and looking to get in front of more investors, make sure to register by tomorrow to save $200 on your registration!
Partial List of Digital RESI March Confirmed Investors
By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series
Digital RESI March will feature a novel entrepreneurial education track, the LSN Global Partnering Campaign and Roadshow Preparation course, which will include six classes total, two classes that will be delivered each day of the 3-day virtual event. This education focus will be for entrepreneurs who are starting to plan for their fundraising and licensing partner search and how LSN can help. An important theme of the education will concern how to plan and execute a global roadshow efficiently, which can greatly determine an early-stage entity’s success when moving from their regional environment to the global competitive landscape. The education sessions are highlighted below:
Participating in the classes will allow the attendees to hear firsthand from LSN Founder and CEO, Dennis Ford, on issues including the importance of getting your company story straight, cogently weaving this narrative through multiple modalities (tagline to pitch deck), and how to avoid some of the most common pitfalls that catch first-time CEOs off-guard. Throughout the sessions on Wednesday (3/15) and Thursday (3/16), participants will hear from members of LSN’s Business Development and Investor Research teams on how to develop a professional set of marketing collateral, what the 10 myths of fundraising are, and strategies to boost partnering success in the global arena.
Attendees of RESI will be able to access the educational content in two methods: either through 1-day and 3-day partnering registrations ($695 and $995 respectively) which include the ability to book meetings with the capital investors and licensing partners who are attending Digital RESI March, or through the Audience Access Pass ($295) which grants full access to all of the education content & panels at Digital RESI March, but with no partnering.
Life Science Nation (LSN) is now focusing our efforts towards planning our upcoming fully virtual conference, Digital RESI, March 14-16. Digital RESI March will include all of the RESI favorites – Investor panels, Innovator’s Pitch Challenge, and workshops. In addition, a NEW entrepreneurial education track, the LSN Global Partnering Campaign and Roadshow Preparation course.
The LSN team hosts virtual webinars leading up to Digital RESI March to help our community of startups prepare for meeting with investors and strategic partners alike. Check out the recordings and sign up for upcoming webinars.
February 1, 12 PM EST
Delivering a Successful Virtual Pitch
The Innovator’s Pitch Challenge (IPC) returns across the upcoming 3-day digital conference, Digital RESI, March 14-16th. Being able to successfully deliver a powerful and compelling pitch to portray why your company’s unique technology should be an investor’s top interest. This workshop gives you tips from the application process, execution of the pitch and preparing for investor-led Q&A.
February 7, 12 PM EST
Tech Hub Exposure at RESI
This webinar is designed for tech hub organizations ranging from accelerators, incubators, non-profits, universities, tech transfer offices, regional organizations, and more who set up their early-stage life science startup constituents for success with their entrepreneurship and fundraising journey. It will showcase the tools and resources that LSN makes available for Tech Hubs to help their startups who’ve raised less than $2M USD in capital expand their outreach from Regional to Global, build a target list of investors, get involved with the RESI conference series, and more.
February 15, 12 PM EST
Tagline & Elevator Pitch
Distilling your company identity into a 5-7 word tagline and then expanding upon that in a 5-7 sentence elevator pitch is one of the most fundamental business development skills that early-stage entrepreneurs must master when launching global partnering campaigns. Join us to learn how to develop a compelling tagline and convincing elevator pitch to grip the attention of your target investors and licensing partners.
March 1, 12 PM EST
Strategies for Successful Partnering
Take a deep dive into your outreach campaign. Learn more about our proven successful strategy and how to craft your messages from your initial outreach and each follow up message after that.
By Erika Wu, Business Development Manager, Global Tech Hubs, LSN
Mansfield Bio-Incubator Chief Operating Officer, Alexander Margulis has been in the Life Sciences industry for over 20 years and is passionate about creating a robust and accessible entrepreneurial community among local universities, startups, and investors. Less than 1-hour away from Boston and Cambridge, the facility provides mentorship, networking opportunities and affordable private and shared spaces for research labs. In addition, they offer several resources such as access to professional advisors and assistance with government and private funding research applications. Currently, Mansfield Bio-Incubator hosts over 20 early-stage startups ranging from therapeutics to medical devices in the life sciences areas of oncology, women’s health, animal health, biomaterials, and more.
Listen to our conversation to learn more about how Alexander and his team are creating, growing, and ensuring the success of the next generation of life science companies at Mansfield Bio-Incubator.
Contact Erika Wu, Business Development Manager, Global Tech Hubs of LSN to learn about tech hub offer.
Next Phase Newsletter 